Abstract
With the large global burden of latent tuberculosis (TB) infection (LTBI), screening for LTBI for various reasons has become standard practice including the low-prevalence settings.
The results showed acceptable intra- and inter-run precision as well as cutoff verification across the two analyzers at the afore-mentioned levels (Table 1). Overall, the LIAISON QFT-Plus showed better inter- and intra-run precision compared with QFT-Plus when comparing low-positive TB1/2 samples; however, coefficient of variation (CVs) less than 20% are generally acceptable for any automated test. Cutoff verification showed CVs for QFT-Plus TB1 and TB2, QFT-Plus LIAISON TB1 and TB2 of 5.2%, 4.1%, 5.2%, 5.4%, respectively, demonstrating robustness around the cutoffs.
Altogether, the two methods were highly comparable. LIAISON QFT-Plus is a suitable alternative to batch testing (e.g., using DSX) in high-volume laboratories.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was deemed a quality improvement project by the Cleveland Clinic Foundation institutional review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Available